CPSE:NOVO BPharmaceuticals
Novo Nordisk (CPSE:NOVO B) Stock Still Looks Cheap As Pipeline Progress Builds
Novo Nordisk stock has given up ground over the past three years, yet broad valuation checks still point to a company that screens as relatively cheap on its current fundamentals. For investors watching the recent pullback, the contrast between weaker returns and a strong value profile is now front of mind.
The share price is down 49.5% over the past three years, which puts the current valuation story in focus rather than recent performance.
Competition with Eli Lilly in GLP-1 weight loss...